Literature DB >> 14531174

Liver support in fulminant liver failure after hemorrhagic shock.

Peter Faybik1, Hubert Hetz, Claus-Georg Krenn, Amir Baker, Peter Germann, Gabriela Berlakovich, Rudolf Steininger, Heinz Steltzer.   

Abstract

Acute liver failure (ALF) is a rare clinical syndrome associated with a mortality of up to 80% and its management remains an interdisciplinary challenge. Despite recent improvements in intensive care management, the mortality of patients with ALF remains high and is related to complications such as cerebral edema, sepsis and multiple organ failure. Emergency orthotopic liver transplantation (OLT) is currently the only effective treatment for those patients who are unlikely to recover spontaneously. Nevertheless, OLT is not always possible because of the shortage of the organs and/or complications related to ALF. Newly introduced liver-assist devices can temporarily support the patient's liver until native liver recovers or can serve as a bridging device until a liver graft is available. The support devices use both cell-based and non-cell-based techniques. One of the latest non-cell-based extracorporeal hepatic support devices, the molecular adsorbent recycling system (MARS), is based on the concept of albumin dialysis. MARS utilises selective hemodiafiltration with countercurrent albumin dialysis aiming to selectively remove both water-soluble and albumin-bound toxins of the low and middle molecular-weight range. We report on a young patient who presented with clinical symptoms of ischemic hepatitis and multi-organ failure (APACHE II score 38-->predicted postoperative mortality 87%) due to prolonged hemorrhagic shock. OLT was contraindicated because of history of pancreas cancer with metastases. It was necessary to use aggressive conservative therapy and an extracorporeal liver-assist device until liver regeneration began and hemodynamic conditions were stable. The patient underwent five treatments with MARS. During the treatment, there were improvements of hemodynamics, respiratory function, acid-base disturbances and laboratory parameters. The plasma disappearance rate of indocyanine green, a parameter of dynamic liver function, improved during MARS treatment. Although repeated neurological examination predicted diffuse brain damage (brain oedema, decreased cerebral blood flow), the patient recovered without any neurological deficits. The patient survived and was discharged from the hospital in good condition. In this case MARS treatment was successful in supporting the patient through the most critical period of ALF.

Entities:  

Mesh:

Year:  2003        PMID: 14531174     DOI: 10.1007/bf03040455

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  13 in total

1.  A new procedure for the removal of protein bound drugs and toxins.

Authors:  J Stange; S Mitzner; W Ramlow; T Gliesche; H Hickstein; R Schmidt
Journal:  ASAIO J       Date:  1993 Jul-Sep       Impact factor: 2.872

2.  Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.

Authors:  Uwe Heemann; Ulrich Treichel; Jan Loock; Thomas Philipp; Guido Gerken; Massimo Malago; Sebastian Klammt; Matthias Loehr; Stephan Liebe; Steffen Mitzner; Reinhardt Schmidt; Jan Stange
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

Review 3.  Review article: the molecular adsorbents recirculating system (MARS) in liver failure.

Authors:  S Sen; R P Mookerjee; N A Davies; R Williams; R Jalan
Journal:  Aliment Pharmacol Ther       Date:  2002-12       Impact factor: 8.171

Review 4.  Acute liver failure.

Authors:  R Q Gill; R K Sterling
Journal:  J Clin Gastroenterol       Date:  2001-09       Impact factor: 3.062

5.  The systemic inflammatory response syndrome in acute liver failure.

Authors:  N Rolando; J Wade; M Davalos; J Wendon; J Philpott-Howard; R Williams
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

Review 6.  Treatment of hepatic failure--1996: current concepts and progress toward liver dialysis.

Authors:  N L Sussman; J R Lake
Journal:  Am J Kidney Dis       Date:  1996-05       Impact factor: 8.860

7.  Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system?

Authors:  S S Awad; S Sawada; O S Soldes; P B Rich; R Klein; W H Alarcon; S C Wang; R H Bartlett
Journal:  ASAIO J       Date:  1999 Jan-Feb       Impact factor: 2.872

8.  [Liver transplantation in acute liver failure].

Authors:  W Yeganehfar; P Wamser; S Rockenschaub; M Schindl; M Mittlböck; E Eisenhuber; C Madl; F Längle; G Berlakovich; F Mühlbacher; R Steininger
Journal:  Wien Klin Wochenschr       Date:  1998-09-04       Impact factor: 1.704

9.  [Prognostic factors in acute liver failure].

Authors:  E Eisenhuber; C Madl; L Kramer; R Steininger; W Yeganehfar; K Ratheiser; A Gangl
Journal:  Wien Klin Wochenschr       Date:  1998-09-04       Impact factor: 1.704

Review 10.  [The artificial liver--an interim report].

Authors:  H G Koebe; F W Schildberg
Journal:  Wien Klin Wochenschr       Date:  1998-09-04       Impact factor: 1.704

View more
  3 in total

1.  Liver support in acute liver failure.

Authors:  Robin D Hughes
Journal:  Wien Klin Wochenschr       Date:  2003-09-15       Impact factor: 1.704

2.  Bridging to transplantation in acute liver failure in a 7-month-old infant.

Authors:  Gerhard Trittenwein; Harald Boigner; Gehan Mostafa; Gudrun Burda; Adolf Mühl; Gabriele Amann; Arnold Pollak
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 3.  [Acute liver failure. Current aspects of diagnosis and therapy].

Authors:  M Bauer; M Paxian; A Kortgen
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.